Background: Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective: To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods: This prospective study enrolled 147 moderate‐to‐severe AD patients, and physician‐ and patient‐reported outcomes were evaluated at multiple time points. Results: Abrocitinib rapidly reduced Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Itch Numeric Rating Scale (Itch‐NRS), and body surface area (BSA) from Week 4 throughout Week 52, with 83.1% and 53.2% of patients achieving EASI‐75 and EASI‐90, respectively, at Week 52. Improvement was less pronounced in the head and neck compared to the trunk and limbs. Shorter disease duration (< 84 months) and the absence of allergic comorbidities predicted better long‐term response. Patients achieving EASI‐75 or EASI‐90 by Week 4 were more likely to maintain control at Week 52. Drug survival was 72.7% at Week 52. Adverse events (AEs) occurred in 61.9% of patients, with acneiform eruptions (19.7%) and gastrointestinal symptoms (17.7%) being most common within Week 12. After 12 weeks, hypercholesterolemia, abnormal liver function, and infections increased. Conclusion: Abrocitinib showed promising long‐term efficacy and safety in Chinese patients with moderate‐to‐severe AD, while consistent lab monitoring is required. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2200063195